These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34835109)

  • 21. The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis-Specific Host Immunity Through the Glucocorticoid Receptor.
    Tomasicchio M; Davids M; Pooran A; Theron G; Smith L; Semple L; Meldau R; Hapgood JP; Dheda K
    J Infect Dis; 2019 Apr; 219(8):1329-1337. PubMed ID: 30452655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
    Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
    Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
    Rahimy MH; Ryan KK
    Contraception; 1999 Oct; 60(4):189-200. PubMed ID: 10640165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1.
    Grivel JC; Elliott J; Lisco A; Biancotto A; Condack C; Shattock RJ; McGowan I; Margolis L; Anton P
    AIDS; 2007 Jun; 21(10):1263-72. PubMed ID: 17545702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoids and medroxyprogesterone acetate synergize with inflammatory stimuli to selectively upregulate CCL20 transcription.
    Moliki JM; Nhundu TJ; Maritz L; Avenant C; Hapgood JP
    Mol Cell Endocrinol; 2023 Mar; 563():111855. PubMed ID: 36646303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
    Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
    Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.
    Kleynhans L; Du Plessis N; Allie N; Jacobs M; Kidd M; van Helden PD; Walzl G; Ronacher K
    Infect Immun; 2013 Apr; 81(4):1234-44. PubMed ID: 23381991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
    Jeppsson S; Gershagen S; Johansson ED; Rannevik G
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 does not provoke alteration of cytokine gene expression in lymphoid tissue after acute infection ex vivo.
    Audigé A; Schlaepfer E; Bonanomi A; Joller H; Knuchel MC; Weber M; Nadal D; Speck RF
    J Immunol; 2004 Feb; 172(4):2687-96. PubMed ID: 14764744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional response of vaginal epithelial cells to medroxyprogesterone acetate treatment results in decreased barrier integrity.
    Woods MW; Zahoor MA; Lam J; Bagri P; Dupont H; Verschoor CP; Nazli A; Kaushic C
    J Reprod Immunol; 2021 Feb; 143():103253. PubMed ID: 33285485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice.
    Wessels JM; Nguyen PV; Vitali D; Mueller K; Vahedi F; Felker AM; Dupont HA; Bagri P; Verschoor CP; Deshiere A; Mazzulli T; Tremblay MJ; Ashkar AA; Kaushic C
    Sci Rep; 2021 Feb; 11(1):3894. PubMed ID: 33594113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.
    Heffron R; Stalter R; Pyra M; Nanda K; Erikson DW; Hladik F; Blue SW; Davis NL; Mugo N; Kourtis AP; Lingappa JR; Baeten JM;
    AIDS; 2019 Mar; 33(4):735-744. PubMed ID: 30585845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion.
    Quispe Calla NE; Vicetti Miguel RD; Aceves KM; Torres A; Cherpes TL
    Contraception; 2019 Nov; 100(5):397-401. PubMed ID: 31302121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.
    Kourtis AP; Haddad L; Tang J; Chinula L; Hurst S; Wiener J; Ellington S; Nelson JA; Corbett A; De Paris K; King CC; Hosseinipour M; Hoffman IF; Jamieson DJ
    Contemp Clin Trials; 2017 Jan; 52():27-34. PubMed ID: 27836505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid-like actions of medroxyprogesterone acetate upon MtTW15 rat mammosomatotropic pituitary tumors.
    Winneker RC; Parsons JA
    Endocrinology; 1981 Jul; 109(1):99-105. PubMed ID: 6453713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk.
    Irvin SC; Herold BC
    PLoS One; 2015; 10(3):e0121135. PubMed ID: 25798593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
    Zalenskaya IA; Chandra N; Yousefieh N; Fang X; Adedipe OE; Jackson SS; Anderson SM; Mauck CK; Schwartz JL; Thurman AR; Doncel GF
    J Clin Invest; 2018 Oct; 128(10):4622-4638. PubMed ID: 30222141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice.
    Wessels JM; Lajoie J; Cooper MIJH; Omollo K; Felker AM; Vitali D; Dupont HA; Nguyen PV; Mueller K; Vahedi F; Kimani J; Oyugi J; Cheruiyot J; Mungai JN; Deshiere A; Tremblay MJ; Mazzulli T; Stearns JC; Ashkar AA; Fowke KR; Surette MG; Kaushic C
    Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31537512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice.
    Quispe Calla NE; Vicetti Miguel RD; Glick ME; Kwiek JJ; Gabriel JM; Cherpes TL
    J Int AIDS Soc; 2018 Jan; 21(1):. PubMed ID: 29334191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.